about
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian CarcinomasPredicting survival in head and neck squamous cell carcinoma from TP53 mutation.Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancersGene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancerTP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.Integrative network analysis for survival-associated gene-gene interactions across multiple genomic profiles in ovarian cancer.Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progressionSpecific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cellsScreening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysisThe Regulation of Cellular Functions by the p53 Protein: Cellular Senescence.
P2860
Q28547093-78F51958-1624-4082-961C-90B3E1B67ABBQ30365539-8528CF77-6E38-4AED-8C00-8CC5B28969F5Q30377229-BBCB3316-29EC-4575-8141-5411BAD0E7E4Q33598237-72132322-B1AA-425B-9C11-F424691509E6Q34775855-432B8C42-71BD-42FD-AB5F-AFCC9712BECBQ35817496-16BBF368-7E59-4E15-A5D8-373333C73474Q35820674-986FAAB5-82A0-4B02-8C41-DB5DC2C48248Q35856294-0B3F3312-4156-4B7D-AC07-36F8D96E6D20Q36309603-EBC2C38F-FC9A-4B6E-A982-AAC94E94F044Q36416465-36379AF4-DED9-432B-8B28-1F2605563A40Q36545843-482691A0-A74A-45C7-B709-DD702535BD63Q36979335-5586F6C7-A4AD-4A97-9393-E45E13B89B4CQ37706855-1E4B188A-2B81-49FC-A782-D862CB562372Q38686022-9A0CDEA7-64FE-4D70-81FC-B4EBE1994A77Q39018419-5913E341-1458-4823-96D8-026EE8854602
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Poor survival with wild-type TP53 ovarian cancer?
@ast
Poor survival with wild-type TP53 ovarian cancer?
@en
type
label
Poor survival with wild-type TP53 ovarian cancer?
@ast
Poor survival with wild-type TP53 ovarian cancer?
@en
prefLabel
Poor survival with wild-type TP53 ovarian cancer?
@ast
Poor survival with wild-type TP53 ovarian cancer?
@en
P2093
P2860
P1433
P1476
Poor survival with wild-type TP53 ovarian cancer?
@en
P2093
Anil K Sood
Daisy I Izaguirre
David M Gershenson
Erin R King
Kwong-Kwok Wong
Michael T Deavers
Samuel C Mok
Suet-Yan Kwan
P2860
P304
P356
10.1016/J.YGYNO.2013.06.016
P407
P577
2013-06-22T00:00:00Z